Faldaprevir And Simeprevir Outshine Today’s Protease Inhibitors
Executive Summary
Phase III data for once-daily protease inhibitors demonstrate advantages over the currently approved candidates in the class, which are given three times daily. But in the rapidly changing and highly competitive hepatitis C market, just where these next-generation drugs might fit in remains unclear.